Antimicrobial activity, bacterial sensitivity, intermediate sensitivity and resistance to antibiotics commonly used against coagulase-negative Staphylococcus spp, Staphylococcus epidermidis and Enterococcus faecalis
Antimicrobial drug | Coagulase-negative Staphylococcus spp (26 isolates) | S epidermidis (16 isolates) | E faecalis (15 isolates) | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MIC50 | MIC90 | S% | I% | R% | MIC50 | MIC90 | S% | I% | R% | MIC50 | MIC90 | S% | I% | R% | |
Fosfomycin tromethamine* | 0.25 | 32 | 96.2 | 0.0 | 3.8 | 0.25 | 0.5 | 100.0 | 0.0 | 0.0 | 32 | 32 | 100.0 | 0.0 | 0.0 |
Levofloxacin | 0.5 | 128 | 50.0 | 0.0 | 50.0 | 4 | 128 | 43.8 | 0.0 | 56.2 | 8 | 32 | 40.0 | 0.0 | 60.0 |
Moxifloxacin | 0.125 | 16 | 50.0 | 23.1 | 26.9 | 1 | 16 | 43.8 | 31.2 | 25.0 | 1 | 8 | – | – | – |
Cefdinir | 0.5 | >256 | 61.5 | 11.6 | 26.9 | 0.5 | >256 | 56.3 | 12.5 | 31.2 | 1 | >256 | – | – | – |
Cefixime | 16 | >256 | – | – | – | 16 | >256 | – | – | – | 8 | >256 | – | – | – |
Cefaclor | 4 | 64 | 69.2 | 19.3 | 11.5 | 4 | 64 | 68.8 | 18.7 | 12.5 | 64 | >256 | – | – | – |
Cefprozil | 1 | 32 | 88.5 | 0.0 | 11.5 | 1 | 32 | 87.5 | 0.0 | 12.5 | 8 | 64 | – | – | – |
Cefuroxime | 1 | 128 | 88.5 | 0.0 | 11.5 | 1 | 128 | 87.5 | 0.0 | 12.5 | 8 | >256 | – | – | – |
Amoxicillin/clavulanic acid | 0.5 | 16 | 88.5 | – | 11.5 | 0.25 | 16 | 87.5 | – | 12.5 | 0.5 | 2 | – | – | – |
Cefotaxime | 2 | 16 | 88.5 | 7.7 | 3.8 | 2 | 16 | 87.5 | 12.5 | 0.0 | 2 | >256 | – | – | – |
Azithromycin | 64 | >256 | 15.4 | 0.0 | 84.6 | >256 | >256 | 18.8 | 0.0 | 81.2 | >256 | >256 | – | – | – |
Nitrofurantoin | 16 | 32 | 100.0 | 0.0 | 0.0 | 16 | 32 | 100.0 | 0.0 | 0.0 | 32 | 32 | 100.0 | 0.0 | 0.0 |
Oxacillin | 0.5 | 128 | 38.5 | – | 61.5 | 0.5 | 128 | 37.5 | – | 62.5 | – | – | – | – | – |
*Determination of the breakpoint of fosfomycin tromethamine to Enterobacteriaceae (sensitivity rate ≤64 mg/L; resistance rate ≥256 mg/L).
I, intermediate; MIC, minimal inhibitory concentration; R, resistant; S, susceptible.